BridgeMD
New treatment option for Brain Metastases
Official title Neoadjuvant Stereotactic Radiotherapy for Brain Metastasis
ClinicalTrials.gov ID: NCT06933199
What this study is testing
- What it's testing
- This multicentre proof-of-concept study, involving 4 centers, aims to establish the value of fractionated neoadjuvant stereotactic radiotherapy (NaSRT) as a new treatment paradigm for brain metastases (BM) in the frame of the Czech neurooncology network. Most relevant studies published to date used single-fraction radiotherapy and dealt with the inherent bias related to their retrospective nature.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- Karnofsky Performance Status ≥ 60
- Histologically verified primary cancer disease
- MRI findings indicating BM
- Target BM indicated for surgical resection and any other metastases suitable for radical SRT.
You likely can't join if
- Confirmed hematological malignity
- Small-cell (lung) carcinoma
- Peracute condition requiring immediate neurosurgical intervention
- History of whole-brain radiotherapy (WBRT)
- History of stereotactic radiotherapy to a target brain metastasis
- Pregnancy
See the full eligibility criteria
- Age ≥ 18 years
- Karnofsky Performance Status ≥ 60
- Histologically verified primary cancer disease
- MRI findings indicating BM
- Target BM indicated for surgical resection and any other metastases suitable for radical SRT.
- Target BM between 1 cm and 7 cm at the longest diameter on T1 post-contrast MR imaging
- Confirmed hematological malignity
- Small-cell (lung) carcinoma
- Peracute condition requiring immediate neurosurgical intervention
- History of whole-brain radiotherapy (WBRT)
- History of stereotactic radiotherapy to a target brain metastasis
- Pregnancy
- Inability to perform surgical resection of the target BM within 7 days after NaSRT
The study team makes the final eligibility decision.
Where it's taking place
- Ostrava, Moravian-Silesian Region, Czechia
- Brno, Czechia
- Hradec Králové, Czechia
- Olomouc, Czechia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ostrava, Moravian-Silesian Region, Czechia; Brno, Czechia; Hradec Králové, Czechia; Olomouc, Czechia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.